MAP2K1 and RASopathy: For example, treatment with MEK1/2 inhibitors during postnatal stages reverses cardiac deficits and tumorigenesis in RASopathy models and patients with NS (Andelfinger et al., 2019; Hilal et al., 2023; Wu et al., 2011).